Portal de investigación
I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ELI LILLY AND COMPANY
Cita
I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease. (I5T-MC-AACO). ELI LILLY AND COMPANY. 2025IP:MIGUEL BAQUERO TOLEDO.